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A B S T R A C T
Objective: To evaluate the effectiveness of an innovative strategy to improve implementation of evidence-based
guidelines on the management of hypertension in pregnancy compared to a common strategy of professional
audit and feedback.
Design: Cluster randomized controlled trial (c-RCT).
Setting: Sixteen Dutch hospitals.
Population: All patients with a hypertensive disorder during pregnancy who were admitted to one of the par-
ticipating hospitals between April 1st 2010 and May 1st 2011, were suitable for inclusion; the only exclusion
criterion was the presence of lethal fetal abnormalities.
Methods: Hospitals were randomly assigned to either an innovative implementation strategy including a com-
puterized decision support system (DSS) and professional audit and feedback or a minimal implementation
strategy of audit and feedback only.
Main outcome measures: Primary outcome measure was a combined rate of major maternal complications.
Secondary outcome measures included process-related measures on guideline adherence, and patient-related
outcomes. A process evaluation was performed alongside.
Results: No statistically significant difference was found in both the occurrence of major complications and most
secondary outcome measures between the two groups. Process evaluation showed limited use of the compu-
terized DSS, with a large variation between hospitals (0–49,5% of the eligible patients), but positive experiences
of actual users.
Conclusion: Using a computerized DSS for implementation of the clinical guidelines for the management of
hypertension in pregnancy did not result in fewer major maternal and fetal complications. Limited use of the DSS
in the innovative strategy group could be an explanation for the lack of effect.
1. Introduction
Seventeen percent of all clinical pregnancies are complicated by
hypertension and two percent by preeclampsia [1–6]. Hypertensive
disorders in pregnancy are one of the main causes of maternal mortality
and morbidity worldwide. Several clinical guidelines have been de-
veloped worldwide to provide pregnant women with hypertensive
disorders with the best available healthcare [7]. Purpose of clinical
guidelines is to support healthcare providers, decrease practice varia-
tion, and ultimately improve patient outcomes. However, the mere
existence of these guidelines does not automatically imply that they are
widespread or commonly used. Case analyses of adverse maternal
outcomes showed a high level of substandard care [8]. Dissemination of
new guidelines should ideally be followed by robust implementation
efforts. Research on the implementation of obstetrical guidelines is
scarce. It is commonly known in guideline implementation research
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that there is no ‘magic bullet’ for successful implementation of every
clinical problem or in every practice setting [9–12]. The most fre-
quently studied interventions encompass audit and feedback on current
practice, dissemination of educational materials, reminders and the
organization of educational meetings or outreach visits, which all seem
to have only small to moderate effects on the improvement of profes-
sional performance [13–15].
Chaudry et al., demonstrated a major benefit of implementing
health information technology on increased adherence to guideline-
based care, amongst others in hypertension [16]. Different health in-
formation technology systems were reviewed. Most of them included a
decision support system (DSS), and some integrated clinical guidelines
[17]. In 2005–2006, the departments of Obstetrics and Gynecology of
the VU University Medical Centre in Amsterdam and the University
Medical Centre Utrecht tested and evaluated the feasibility of using a
DSS for the Dutch Society of Obstetrics and Gynecology (NVOG)
guideline on the treatment of prevention of neonatal Group B Strepto-
coccus disease. In the evaluation, the DSS appeared feasible in clinical
practice: most users (95%) were satisfied with its use and 78% would
prefer to maintain and extend the DSS to other NVOG guidelines
[18,19]. We hypothesized that an implementation strategy including a
DSS may lead to a higher compliance to the guidelines’ recommenda-
tions on hypertensive disorders in pregnancy [20,21] and thus a lower
rate of maternal complications than a minimal implementation strategy
consisting of a single intervention of audit and feedback only. We de-
signed a cluster randomized controlled trial (c-RCT), the BIG CHANGE
(BOS supported Implementation of Guidelines on Clinical Hypertension
and its mANagement in GEstation) trial, to study the effects of an in-
novative implementation strategy to improve the use of national ob-
stetrical guidelines on hypertension in pregnancy, consisting of a multi-
faceted intervention (computerized DSS plus audit and feedback), tai-
lored to barriers from the literature and directed at obstetrical profes-
sionals. To increase our understanding of factors influencing the impact
of the implementation strategy, a process evaluation of the trial was
also performed.
2. Materials and methods
2.1. Study design
We performed a c-RCT in 16 hospitals in three regions of The
Netherlands. The research ethics committee of VU University Medical
Centre approved the study. The trial was registered with trialregister.nl
(ID NTR 1387). Further details of the study design have been described
elsewhere [22].
2.2. Randomization
Hospitals were randomly assigned to either the innovative im-
plementation strategy group (computerized DSS plus audit and feed-
back) or the minimal implementation strategy group (audit and feed-
back only). Prior to randomization, participating hospitals were
stratified according to function (academic hospitals, teaching hospitals
and non-teaching hospitals). To ensure concealment of treatment allo-
cation two research associates, blinded for characteristics of the clinics,




All 16 hospitals that were invited agreed to participate. Two of them
were large, academic hospitals, nine hospitals were medium-sized,
teaching hospitals; the other five were small, non-teaching hospitals.
The different types were chosen to reflect national obstetrical care.
2.3.2. Patients
All patients with a hypertensive disorder during pregnancy who
were admitted to one of the participating hospitals were suitable for
inclusion; the only exclusion criterion was the presence of lethal fetal
abnormalities. A pre-implementation measurement was performed in
each hospital, which included a random sample of patients that were
admitted with a hypertensive disorder during their pregnancy in 2008.
For the measurement after introduction of both implementation stra-
tegies, all patients admitted to one of the hospitals between April 1st
2010 and May 1st 2011 with a hypertensive disorder during their
pregnancy were included.
2.4. Study interventions
2.4.1. Minimal implementation strategy
The minimal implementation strategy, implemented in 8 hospitals,
was directed at professionals (obstetricians and gynecologists) and
consisted of professional audit and feedback. Audit comprised results of
the pre-implementation measurement of the hospital’s scores to 12
previously developed quality indicators (Table 1) regarding care pro-
vided in 200823. Based on these indicator scores, hospital-specific
feedback reports were formulated by the study group. The contact
person of each hospital was sent a feedback report by email, asking
them to forward copies to their colleagues (i.e. gynecologists, residents
and clinical midwifes). An instruction letter was enclosed to facilitate
interpretation of the feedback report. Feedback on current care was
Table 1
Final set of key recommendations eligible for indicator transcription per guideline and indicator-type.
Guideline 'Hypertensive disorders in pregnancy' Type of indicator
Patients with severe preeclampsia need to be adequately stabilized before intervention (transport to tertiary care centres and/or delivery). Treatment exists of
magnesium sulphate and/or antihypertensive drugs depending on the blood pressure.
Process
First treatment to prevent eclampsia needs to exist of magnesium sulphate. Process
When improvement fails to occur or deterioration occurs with patients with severe preeclampsia, the physician needs to terminate the pregnancy. Process
Systolic blood pressure ≥ 170mmHg and/or diastolic blood pressure ≥ 110mmHg in a patient with gestational hypertension or preeclampsia needs to be
treated with drugs.
Process
Target values for the systolic blood pressure are 140–160mmHg and 90–105mmHg for the diastolic blood pressure in patients with preeclampsia. Process
Patients with moderate-severe gestational hypertension need to be informed by their physician about the possibility of acute worsening of the disorder and
the necessity to contact their physician when experiencing symptoms.
Process
The physician needs to perform laboratory examination: haemoglobin, haematocrit, creatinine, platelets, lactate dehydrogenase (LDH) and alanine
aminotransferase (ALAT) in case a patient presents with subjective symptoms of preeclampsia, in case of proteinuria or severe (gestational) hypertension.
Process
Treatment of patients with severe preeclampsia needs to be a clinical one. Process
The physician needs to start magnesium sulphate when a patient has symptoms of severe preeclampsia. Process
The physician needs to perform urine examination for proteinuria when a patient is diagnosed with gestational hypertension. Process
The hospital needs to have a regional consent concerning consultation or transportation to a perinatal centre for patients with severe preeclampsia before
32 weeks gestation or severe maternal morbidity.
Structure
Every hospital needs to have a (local) protocol for treatment of patients with gestational hypertension, preeclampsia or HELLP. Structure
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given by means of a bar chart showing the total range of performance
per quality indicator on a scale from 0 to 100% including the median
adherence of all participating hospitals and the median of its peer
hospitals (academic, teaching, non-teaching). Each individual hospital
also received a clear marking of their performance in the bar chart, but
hospitals did not get information of the performance of other individual
hospitals. This was only available on aggregate level. No further contact
was established with the minimal implementation strategy hospitals
until the data collection for the post-implementation measurement was
started.
2.4.2. Innovative implementation strategy
The innovative strategy, implemented in the other 8 hospitals, was
multi-faceted and included the following two professional-oriented
elements:
(i) Audit and feedback discussions: Similar to the minimal strategy,
hospital-specific feedback reports were developed and sent to the
eight innovative implementation strategy hospitals in April 2010.
After four weeks, a multi-disciplinary (e.g. addressing gynecolo-
gists, residents and clinical midwifes) meeting was organized in
each hospital in which the feedback report was presented and
commented by one of the authors. During each meeting, the hos-
pital’s performance was compared with the other 15 hospitals’
performances and possibilities for quality improvement were dis-
cussed.
(ii) A computerized DSS, including a web-application, was developed
(by Giant Soft, Leeuwarden, The Netherlands) to assist the profes-
sionals in providing optimal care for the patients admitted to their
hospital22. For each patient and fetus several characteristics had to
be filled in: gestational age, systolic and diastolic blood pressure,
complaints of headache, pain in upper right part of the abdomen,
vision problems, if laboratory testing was done and if so, were they
normal or abnormal, if urine had been tested for proteinuria and if
so, what was the result. The fetal characteristics contained fetal
growth and cardiotocography (CTG) findings. When all data were
entered in the DSS, recommendations of the Dutch guideline re-
garding hypertensive disorders in pregnancy, tailored to the spe-
cific woman, were provided within seconds.
2.5. Outcomes
The primary outcome of this trial was a combined rate of major
maternal complications (maternal death, organ specific complications
of hypertension, HELLP syndrome and placental abruption). All medical
records were checked on the presence of these complications both in
the pre- and post-implementation measurement.
Secondary outcome measures included process-related measures on
guideline adherence, and patient-related outcomes (caesarean delivery
rates, and rates of neonatal mortality and morbidity). Guideline ad-
herence rates were measured using quality indicators. These indicators
(structure and process indicators) were extracted from two obstetrical
guidelines of the NVOG: ‘hypertensive disorders in pregnancy’ and
‘chronic hypertension and pregnancy’ [20–21] and systematically de-
veloped [23]. Adherence to guideline indicators was scored dichot-
omously, ‘adherence’ vs. ‘non-adherence’. The indicators covered topics
like ‘indications for treatment’, ‘treatment options’, ‘patient monitoring’
and ‘patient information’. All indicators were tested during the pre-
implementation measurement for several quality criteria (i.e. measur-
ability, reliability, applicability, improvement potential, discriminatory
capacity and complexity), thus exploring their value for monitoring and
improving clinical performance. After the pre-implementation mea-
surement, indicators with high measurability, reliability and applic-




Data were collected from medical records (e.g., maternal compli-
cations, process measures on guideline adherence and secondary pa-
tient-related outcomes). Each record was verified to determine the
presence or absence of major maternal complications, caesarean de-
livery, rates of neonatal mortality and morbidity. Items necessary to
calculate the quality indicators were collected as well. Medical record
extraction was performed by two trained data collectors who entered
data in digital forms, specifically designed to enhance systematic and
complete data collection by using computerized algorithms for data
entry.
2.6.2. Process evaluation
We also performed a process evaluation of the innovative im-
plementation strategy to assess use of and experiences with the DSS. In
all eight hospitals randomized to this strategy residents and clinical
midwifes collected user data. In addition, professionals involved in
obstetric care were contacted and asked to fill in an online ques-
tionnaire containing questions on efficiency (time saving and appro-
priate advice), barriers (familiarity, accessibility and applicability of
DSS) and points for improvement (legibility, extension, clarity an ex-
pansion of DSS). An email containing a link to the questionnaire was
sent to all users.
2.7. Sample size and feasibility
The rate of major maternal complications in 216 Dutch patients
with severe hypertension or preeclampsia was reported as 34% [24,25].
In 96% of cases of maternal death, The Dutch Maternal Mortality
Committee determined several factors of substandard care, which were
classified as insufficient treatment of hypertension in about half of these
[8,26]. It was expected that an increased adherence to the guidelines’
recommendations would reduce the number of major maternal com-
plications by half, i.e. from 34% to 17%. Considering an intracluster
Step 2 Questionnaire round (rating and adding by expert 
l)
Step 3 Panel consensus meeting 
Step 4 Critical evaluation 
Step 5 Consultation with guideline developers  
and conversion into quality indicators 
17 candidate quality indicators 
14 quality indicators 
14 key recommendations suitable for converting into quality indicators 
14 candidate quality indicators 
Step 1 Deriving key recommendations from national guidelines 
48 key recommendations 
Fig. 1. A step-wise RAND-modified Delphi method to develop quality indicators
for care for patients with hypertensive disorders in pregnancy.
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correlation of 0.05, 16 hospitals had to be included with approximately
25 patients each in order to get a reliable estimate (alpha= 0.05;
power 0.80) of a 50% difference (34% vs. 17%) in major maternal
complications between both groups. We assumed that 15% of partici-
pants would drop-out or be lost to follow-up, so 472 eligible women
needed to be included, 236 in the innovative implementation strategy
arm and 236 in the minimal implementation strategy arm.
2.8. Analysis
Data were analyzed using IBM SPSS Statistics 20. To analyze the
difference in effectiveness of the innovative implementation strategy
compared to the minimal strategy on the primary and secondary out-
comes, we assessed the proportion of patients that developed major
complications before and after the implementation period in both
groups. Also, both groups were compared with each other, before and
after the implementation period. For each complication, generalized
estimating equation (GEE) models were used to control for the de-
pendency of observations within hospitals in which ‘implementation
strategy’ acted as the independent variable and ‘complication score’ as
the dependent variable.
To analyze the difference in effectiveness of the two strategies on
process-related measures, we assessed the proportion of patients that
were treated in accordance with the guidelines. Quality indicator scores
before and after the implementation period in both intervention groups
were assessed. Within and between group differences were analyzed
with adjustment for clustering of patients within clinics. Therefore, for
each indicator, also GEE models were used in which ‘implementation
strategy’ acted as the independent variable and ‘indicator score’ as the
dependent variable.
For the data analyses of the process evaluation descriptive statistics
were used, both regarding usage rates of (% of eligible patients for
which the DSS was used) and experiences with the DSS. Wilcoxon
signed rank test with a two-sided confidence interval of 5% was used
for the comparison between the two groups.
All analyses were based on the intention-to-treat principle, meaning
all participants were included in the analysis in the group to which they
were originally assigned, regardless of whether they received the im-
plementation strategy or not. Differences in the pre-implementation
measurement period were corrected for by including these scores as a
covariate in the final GEE model.
3. Results
3.1. Participant flow
In the pre-implementation measurement period, 270 patients were
included in the innovative and 262 in the minimal implementation
strategy group. In the post-implementation measurement period, 947
patients were included in the innovative strategy group and 815 pa-
tients in the minimal strategy group.
3.2. Comparability of groups
Demographic characteristics of both groups at both measurement
periods are shown in Table 2.
Both groups are comparable on both measurement moments.
3.3. Outcomes and estimation
3.3.1. Primary outcomes
Table 3 and 4 show the rates of the primary outcomes before and
after the implementation in both groups. Major maternal complications
were statistically significant lower post-implementation in both the
innovative implementation and the minimal implementation strategy
group when compared to the pre-implementation results (OR 0.64
[95% CI 0.42–0.96] and OR 0.70 [95% CI 0.55–0.89], respectively).
There was neither a statistically significant difference in the occurrence
of major complications between the innovative implementation group
and the minimal implementation strategy group pre-implementation
(OR 0.77; 95% CI 0.41–1.42) nor post-implementation (OR 1.13; 95%
CI 0.66–1.9).
3.3.2. Secondary outcomes
Table 5 shows the results for the secondary patient-related out-
comes. Between pre- and post-implementation there was a statistically
significant increase in neonatal mortality (OR 3.30;1.83–5.96) and
decrease in caesarean sections (OR 0.47;0.50–0.76) in the minimal
implementation group; there were no significant changes in the in-
novative implementation group. There were no statistically significant
differences between the two groups on any of these outcomes pre- nor
post-implementation. Table 6 shows the indicator scores for guideline
adherence. Results demonstrated that in both the innovative and the
minimal implementation strategy group guideline adherence improved
after implementation. Laboratory testing statistically significantly im-
proved more in the innovative implementation strategy group com-
pared to the minimal implementation strategy group.
3.4. Process evaluation
The actual use of the DSS showed that data from in total 234 pa-
tients (24.7%) were entered in the innovative computerized system.
The highest usage rate per hospital was 49.5%, the lowest 0%. Most
patients were included in 5 out of 8 hospitals, usage rates ranging from
20% to 49.5% (Fig. 2).
Gynecologists, residents and clinical midwifes of six of the eight
hospitals in the innovative strategy group answered the questionnaire
regarding the process evaluation. A total of 34 (68%) completed
questionnaires were used for analysis. Positive opinions on user
friendliness, clarity, speed of the program, lay-out, clearness and end
report varied from 73.5% to 100% of the participants. On the question
if a DSS was a suitable tool for implementation of a guideline, 91%
answered affirmative. Most of the respondents (85%) found it useful to
develop a computer based support system for other NVOG guidelines,
and 79% intended to use a DSS, if available, for other guidelines. Fifty-
eight percent found using DSS easier than their local protocol or the
NVOG guideline. Improvements mentioned by the respondents con-
cerned the lay-out, and login name and password. Login names and
passwords were provided by the research team, but most respondents
preferred choosing their own login and password.
3.5. Discussion
We report results of a randomized controlled trial that evaluated the
implementation of obstetrical guidelines concerning hypertensive dis-
orders in pregnancy comparing a multifaceted innovative and a
minimal implementation strategy. The multifaceted innovative im-
plementation strategy consisted of a computerized decision support
system combined with audit and feedback, the minimal implementation
strategy of audit and feedback only. There were no statistically sig-
nificant differences in clinical outcomes between the innovative im-
plementation strategy group and the minimal implementation strategy
group. The innovative implementation strategy increased guideline
adherence on one item only, particularly an improvement in laboratory
testing. Process evaluation showed limited use of the computerized
DSS, with a large variation between hospitals (0–49,5%), but positive
experiences of actual users.
We consider the significant improvement in laboratory testing in the
innovative implementation strategy group mainly a finding by chance,
because it is difficult to explain why there was a higher rate of la-
boratory tests, and the estimates were rather uncertain as the con-
fidence intervals were wide.
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Not having found a statistically significant effect of the innovative
implementation strategy raises the question whether this strategy is
ineffective, or whether ineffectiveness is largely caused by flaws in the
study design or incomplete execution of the intervention strategy. We
will further elaborate on these possibilities.
During the study period, obstetric management of hypertensive
disorders in the Netherlands was significantly changed by the results of
the HYPITAT trial [27]. This multicenter, parallel, open-label rando-
mized controlled study was conducted between October 2005 and
March 2008 in 6 academic and 32 non-academic Dutch hospitals. It was
then demonstrated that induction of labour is associated with improved
maternal outcome in women with mild hypertensive disease beyond
37weeks' gestation [27]. A recent evaluation showed that participation
in the HYPITAT trial has led to an increase of induction of labour from
58.3 to 67.1% (P < 0.001) and a decrease of prevalence of eclampsia
from 0.85 to 0.19% (P < 0.001) before and after the trial in the
Netherlands [28]. The results of this study could explain why there is no
difference in clinical outcomes between the innovative strategy group
and the minimal strategy group. Expectative management for these
disorders has decreased compared to the period before the HYPITAT
trial and awareness of the possible maternal and neonatal complications
has increased, which may have lowered the incidence of these com-












2008 2008 2011 N=947
N=262 N=262 N=815
Age 31.32 30.88 30.97 31.44 0.755 0.254
Parity
-Nulliparous 185 188 556 654 0.650 0.850
-Multiparous 77 82 259 293
Gestation
-Term 163 176 651 696 0.614 0.527
-Preterm 98 93 162 251
Ethnicity
-Dutch 204 204 472 654 0.587 0.507
-Mediterranean 29 26 30 49
-Other 15 18 12 30
European 2 7 1 5
-Hindu 8 13 22 31
-African 2 2 10 22





80 86 367 337 0.411 0.825
-Preeclampsia (PE) 126 119 259 408
-HELLP 7 11 10 16
-Superimposed PE 31 28 94 111
-PIH and HELLP 4 4 23 26
-PE and HELLP 14 19 44 46
Multiple pregnancy
-Twin 13 9 18 44 0.869 0.389
Origin
-Midwife 190 186 619 682 0.889 0.204
-Non academic hospital 58 75 179 215
-Academic hospital 14 9 16 44
*p innovative implementation (intervention) 2008 vs minimal implementation (control) 2008.




2008 N=270 2011 N=947 OR (95% CI)
38 (14.1%) 100 (10.6%) 0.64 (0.42–0.96)
2
2008 N=262 2011 N=815 OR (95% CI)














100 (10.6%) 104 (12.8%) 1.13 (0.66–1.9)
1. Innovative implementation strategy group 2008 vs 2011.
2. Minimal implementation strategy group 2008 vs 2011.
3. Innovative implementation strategy group 2008 vs minimal implementation
strategy group 2008.
4. Innovative implementation strategy group 2011 vs minimal implementation
strategy group 2011.
Table 4
Percentage of major complications for the innovative implementation strategy
and the minimal implementation strategy.








44/262 (16.8) 104/815 (12.8%) 0.70 (0.55–0.89)
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groups after the study period confirms our hypothesis (Table 3).
As an attempt to reduce the high perinatal mortality in the
Netherlands, a nationwide implementation of audits was started in
2009. During a perinatal audit (local, regional or national) health care
professionals (gynecologists, midwives, pediatricians, nurses and pa-
thologists) critically analyze in a structured way the care provided in
cases of perinatal death. These audits resulted in a greater focus on the
possible causes of perinatal mortality and this may have led to in-
creased awareness of the risks of pregnant women with hypertensive
disorders during our study period in both the innovative strategy group
and the minimal strategy group.
In addition, the researchers of the LEMMON study, a Dutch pro-
spective study of severe maternal morbidity conducted between 2004
and 2006 [29], published several articles in 2008 and 2009. They
collected 2552 cases of severe maternal morbidity. Substandard care
was found in 62% of these cases through clinical audit. These results
may also have contributed to more awareness and the improvement of
care for pregnant women in both groups.
Besides a reduction in major maternal complications during the
study period in both groups the rate of major maternal complications
before implementation of the guideline in 2010–2011 was lower than
expected based on the results of previous studies. This may be explained
by the fact that our study was performed in academic as well as non-
academic hospitals, whereas former studies [24,25] were performed in
academic hospitals only, thus including a high-risk population.
With regard to the effectiveness of implementation strategies, their
success depends on optimal use and positive experiences. Insight into
these factors could be obtained in a process evaluation. In our study, the
difference between the innovative and minimal strategy was the DSS, so
we particularly included a process evaluation of the DSS. The majority
of patients were included in the intervention group in 5 out of 8 hos-
pitals of the innovative implementation strategy group. One hospital
did not include a single patient, despite several reminders. Although the
users were generally enthusiastic about the DSS, ultimately, in only a
quarter of all eligible patients the DSS was used. This could also explain
the ineffectiveness of the DSS.
A reason for not using the DSS could be that it was not integrated in
the routine of daily practice. A systematic review from Chaudhry et al.
demonstrated that the effectiveness of a computerized DSS was higher if
it was integrated in an electronic patient file [16]. We hypothesize that
using computerized DSS to implement evidence based guidelines could
be more effective when the system is combined with an automatically
imbedded system of reminders, therapeutic suggestions and diagnosis-
specific links to guidelines [30]. Besides, results from a comparable
study among gynecologists of Mourad et al. showed that professionals
either were quite indifferent to an innovative strategy type or did not
consider it their job to do so [31].
Moreover, several Cochrane systematic reviews have shown that the
impact of different strategies to promote healthcare interventions is
widely variable, mostly with small to modest effects on improving
professional practice [15]. Our assumption that an increased adherence
to the guidelines’ recommendations will reduce the number of major
maternal complications by half (50%) was most likely too optimistic. A
review of evidence-based strategies for implementing guidelines in
obstetrics showed especially positive effects for interventions including
audit and feedback, reminders and multifaceted strategies [32]. Al-
though it is clearly demonstrated that the prospective identification of
barriers to change leads to better adaptation of interventions, this was
not demonstrated in our study. Although we used a multifaceted
strategy, including audit and feedback, and adapted the DSS to previous
barriers, we did not find positive effects. As mentioned above, the
limited use of DSS could be an explanation.
3.6. Strengths and weaknesses of the study
One of the strengths of this study is the use of a c-RCT to evaluate
the effect of the tested interventions, as this is considered the ‘gold
standard’ in implementation research [33]. Randomization was per-
formed at hospital rather than professional or patient level to avoid any
risk of contamination of both study arms. Sixteen hospitals participated,
Table 5
Secondary outcomes: patient related outcomes.
1
Innovative implementation group 2011 N=947 Innovative implementation group
2008 N=270
P OR (95% CI)
Neonatal mortality 10 (1.1%) 3 (1.1%) 0.73 0.83 (0.29–2.39)
Dysmaturity 65 (6.9%) 27 (10%) 0.13 0.64 (0.36–1.14)
Asphyxia 72 (7.6%) 19 (7.0%) 0.94 0.98 (0.64–1.52)
Cesarean Section 252 (26.6%) 95 (35.2%) 0.27 0.82 (0.59–1.16)
2
Minimal implementation group 2011 N=815 Minimal implementation group 2008 N=262 P OR (95% CI)
Neonatal mortality 8 (0.99%) 1 (0.38%) < 0.0001 3.30 (1.83–5.96)
Dysmaturity 60 (7.4%) 20 (7.6%) 0.90 0.98 (0.67–1.43)
Asphyxia 44 (5.4%) 19 (7.3%) 0.31 0.77 (0.44–1.29)
Cesarean Section 216 (26.5%) 102 (38.9%) < 0.0001 0.47 (0.50–0.76)
3
Innovative implementation group 2008
N=270
Minimal implementation group 2008
N=262
P OR (95% CI)
Neonatal mortality 3 (1.1%) 1 (0.38%) 0.31 3.12 (0.35–27.86)
Dysmaturity 27 (10%) 20 (7.6%) 0.34 1.41(0.67–3.13)
Asphyxia 19 (7.0%) 19 (7.3%) 0.84 1.05 (0.67–1.65)
Cesarean Section 95 (35.2%) 102 (38.9%) 0.33 0.84 (0.59–1.20)
4
Innovative implementation group 2011 N=947 Minimal implementation group 2011 N=815 P OR (95% CI)
Neonatal mortality 10 (1.1%) 8 (0.99%) 0.76 0.78 (0.15–3.95)
Dysmaturity 65 (6.9%) 60 (7.4%) 0.73 0.94 (0.68–1.31)
Asphyxia 72 (7.6%) 44 (5.4%) 0.10 1.47 (0.93–2.32)
Cesarean Section 252 (26.6%) 216 (26.5%) 0.62 1.10 (076–1.60)
1. Innovative strategy group 2008 vs 2011.
2. Minimal strategy group 2008 vs 2011.
3. Innovative strategy group vs minimal strategy group 2008.
4. Innovative strategy vs minimal strategy group 2011.
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with a good reflection of possible practice variation (academic,
teaching and non-teaching hospitals to represent the Dutch health
system). Another strength is that only two researchers were involved in
checking the medical files. This decreased the chance of interobserver
variation and bias. In addition, our innovative strategy was tailored to
barriers identified by our previous research, which is also seen as a
facilitator for implementation [22].
We realize that there are some limitations to our study as well. An
important one is that this study did not achieve enough statistical
power. We expected that an increased adherence to the guidelines’
recommendations would reduce the number of major maternal com-
plications by half, i.e. from 34% to 17%. This hypothesis appeared to be
wrong, because we overestimated the initial rate and decrease of major
complications, as explained before.
3.7. Conclusions and implications
Using a computerized DSS and audit & feedback for implementation
of the clinical guidelines for the management of hypertension in preg-
nancy did not result in statistically significant less major maternal
complications when compared to a minimal implementation strategy of
audit & feedback only. Process evaluation showed that users of the
computerized decision support system were positive about the system,
but the use of the system could be improved.
4. Ethics approval and consent to participate
Ethical approval was granted June 12th 2008, VUmc. Reference
number 2008/138.
5. Consent for publication
Not applicable.
Table 6
Secondary outcomes process related: guideline adherence.
1
2011 N=947 2008 N=270 P OR (95% CI)
Stabilization 575 (60.7%) 123 (45.6%) 0.0001 3.81 (1.94–7.49)
Mg504 225 (23.8%) 65 (24.1%) < 0.0001 3.95 (2.41–6.46)
Antihypertensive drugs 498 (52.6%) 119 (44.1%) 0.008 1.96 (1.19–3.11)
Blood pressure 919 (97.0%) 240 (88.9%) 0.007 2.66 (1.30–5.43)
Information 242 (25.6%) 160 959.3%) 0.09 0.38 (0.12–1.19)
Laboratory tests 920 (97.1%) 266 (98.5%) 0.0002 13.60 (3.47–53.34)
Urine test 928 (98.0%) 270 (100.0%) 0.78 0.87 (0.47–1.02)
2
2011 N=815 2008 N=262 P OR (95% CI)
Stabilization 454 (55.7%) 187 (71.4%) 0.0001 6.23 (2.44–15.92)
Mg504 194 (23.8%) 62 (23.7%) 0.001 3.76 (1.71–8.24)
Antihypertensive drugs 418 (51.3%) 106 (40.5%) 0.012 3.94 ((1.35–11.52)
Blood pressure 768(94.2%) 245 (93.5%) 0.013 4.00 (1.34–11.94)
information 223 (27.4%) 115 (43.9%) 0.024 0.50 (0.28–0.91)
Laboratory tests 780 (95.7%) 226 (86.3%) 0.92 0.88 (0.06–12.33)
Urine test 794 (97.4%) 270 0.66 0.884 (0.51–1.54)
3
Innovative implementation group 2008 N=270 Minimal implementation group 2008
N=262 P OR (95% CI)
Stabilization 123 (45.6%) 187 (71.4%) 0.78 1.14 (0.46–2.85)
Mg504 65 (24.1%) 62 (23.7%) 0.77 0.90 (0.44–1.83)
Antihypertensive drugs 119 (44.1%) 106 (40.5%) 0.45 1.58 (0.49–5.10)
Blood pressure 240 (88.9%) 245 (93.5%) 0.89 1.08 (0.34–3.40)
Information 160 (59.3%) 115 (43.9%) 0.94 1.05 (0.28–3.99)
Laboratory tests 266 (98.5%) 226 (86.3%) 0.23 0.26 (0.03–2.30)
Urine test 270(100.0%) 258 (98.5%) 0.43 1.87 (0.39–8.92)
4
Innovative implementation group 2011 N=947 Minimal implementation group 2011
N=815 P OR (95% CI)
Stabilization 575 (60.7%) 454 (55.7%) 0.78 0.87 (0.31–2.41)
Mg504 225 (23.8%) 194 (23.8%) 0.93 1.05 (0.37–3.00)
Antihypertensive drugs 498 (52.6%) 418 (51.3%) 0.95 0.97 (0.34–2.79)
Blood pressure 919 (97.0%) 768 (94.2%) 0.85 0.89 (0.26–3.06)
Information 242 (25.6%) 223 (27.4%) 0.41 0.83 (0.53–1.30)
Laboratory tests 920 (97.1%) 780 (95.7%) 0.04 9.72 (1.14–82.92)
Urine test 928 (98.0%) 794 (97.4%) 0.26 1.87 (0.63–5.58)
1. Innovative implementation strategy group 2008 vs. 2011.
2. Minimal implementation strategy group 2008 vs. 2011.
3. Innovative strategy group vs. minimal strategy group 2008.
4. Innovative strategy group vs. minimal strategy group 2011.
Fig. 2. Percentage of patients included in the participating hospitals. X-axis:
number of patients per hospital that should have been included. Y-axis: per-
centage of included patients per hospital.
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6. Availability of data and material
The datasets used and/or analysed during the current study are
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